ARTICLE
Auteur(s) : Sadhanna Badeloe, Jorge Frank
Department of Dermatology and Maastricht University
Center for Molecular Dermatology (MUCMD) and GROW -
School for Oncology and Developmental Biology, Maastricht
University Medical Center, P. Debyelaan 25; Postbus 5800, 6202 AZ
Maastricht, The Netherlands
accepté le 15 Mai 2009
Leiomyomas of the skin were first described by Virchow in 1854
[1]. Cutaneous leiomyomas are rare benign tumors arising from
smooth muscle cells. According to their site of origin they can be
classified into three types, i) those derived from the arrector
pili muscle of hair follicles (piloleiomyomas); ii) those
originating from the vascular smooth muscle (angioleiomyomas); and
iii) those arising from the smooth muscle of genital skin (dartoic
leiomyomas). Piloleiomyoma is the most common type among cutaneous
leiomyomas [1, 2]. In contrast to the mainly solitary
angioleiomyomas and dartoic leiomyomas, piloleiomyomas
predominantly manifest as multiple tumors, referred to as
leiomyomatosis. In 1958 Kloepfer et al. described for the
first time, in an Italian family with cutaneous leiomyomatosis, an
autosomal dominant inheritance pattern with incomplete penetrance
[3]. Subsequently, different authors reported several families with
autosomally dominant inherited cutaneous leiomyomatosis [4-6].
Furthermore, in some of these families, affected female individuals
also exhibited uterine leiomyoma [4, 6]. In 1973, Reed et al.
were the first to emphasize the association with leiomyoma of the
uterus and, therefore, this syndrome was known as Reed’s syndrome
for many years [7]. Currently this syndrome is referred to as
multiple cutaneous and uterine leiomyomatosis syndrome (MCUL; OMIM
150800). In 2001, Launonen et al. reported that a small
proportion of families with MCUL also cluster renal cell cancer
(RCC) [8]. The latter disease variant is referred to as hereditary
leiomyomatosis and renal cell cancer (HLRCC; OMIM 605839). In 2002,
Tomlinson et al. showed that germline mutations in the
fumarate hydratase (FH) gene underlie hereditary cutaneous
leiomyomatosis and its associated features [9].
Clinical features
Cutaneous leiomyomas and leiomyosarcoma
Cutaneous leiomyomas typically present in the second to fourth
decade of life as skin colored or brown-reddish grouped papules or
nodules localized on the trunk and limbs (figure 1A). These benign
tumors are characteristically painful in response to pressure or
low temperature. While the exact pathophysiological origin of pain
in leiomyomas has not yet been elucidated, different authors have
proposed theories, including contraction of smooth muscle cells,
compression or invasion of cutaneous nerve bundles, and an
increased number of nerve elements within the tumors [2, 10-16].
Leiomyomas gradually increase in size and number and the extent of
the skin lesions is variable, even within one family. Some patients
suffer from extensive disease, with multiple leiomyomas covering
large areas of the body, whereas others only have a few
inconspicuous papules.
Interestingly, multiple cutaneous leiomyomas do not exclusively
manifest in a diffuse and symmetric fashion (figure 1B). Rather
frequently, a segmental or band-like manifestation pattern of these
tumors can be observed, most likely reflecting mosaicism [17-39]
(figure 1C).
Already 12 years ago, Happle postulated a genetic concept for the
segmental manifestation of dominantly inherited skin diseases [23].
Whenever the segmental skin lesions reveal the same degree of
severity as that found in the corresponding non-mosaic trait and a
germline mutation is absent, a type 1 segmental involvement is
present. Occasionally, however, the severity of cutaneous
involvement observed in the segmentally affected skin areas is far
more pronounced. Happle suggested that this phenomenon can be
explained by loss of heterozygosity (LOH) at the same locus that
caused the phenotypically less severe, diffuse involvement [23].
Although the type 2 segmental manifestation is usually only rarely
observed, he noted that in cutaneous leiomyomatosis the type 2
segmental manifestation occurs rather frequently. Recently, the
hypothesis for the type 2 segmental manifestation of autosomal
dominant skin disorders has been confirmed on the cellular and
molecular level in Hailey-Hailey disease [40]. In hereditary
cutaneous leiomyomatosis though, this concept has not yet been
demonstrated to be valid.
Malignant transformation of cutaneous leiomyoma is rare.
However, two cases of cutaneous leiomyosarcoma in two different,
apparently unrelated families with hereditary cutaneous
leiomyomatosis and renal cell cancer (HLRCC) have been reported
[41, 42].
Uterine leiomyomas and leiomyosarcoma
Uterine leiomyomas occur in more than 90% of females with MCUL.
These patients may have a medical history of menorrhagia and pelvic
pressure or pain, frequently requiring a hysterectomy before the
age of 30 years [43]. A minority of patients with MCUL/HLRCC
are predisposed to the development of highly aggressive uterine
leiomyosarcoma before the age of 30. Interestingly, this disease
variant has only been observed in the Finnish population to date
[8, 44, 45].
Renal cancer
Type II papillary RCC is the predominant type of kidney cancer in
HLRCC [46]. These tumors tend to be very aggressive. Metastases are
seen in more than 50% of affected individuals, even in those with
relatively small primary tumors. Furthermore, sporadic cases of
collecting duct carcinoma, oncocytoma, and clear cell carcinoma
have been described [46]. Recently, we described a patient with
cutaneous and uterine leiomyoma carrying a heterozygous FH mutation
who also had a history of a metastasizing Wilms tumor (WT) at the
age of 2 years [47]. RCCs in HLRCC are typically solid and
unilateral, although in exceptional cases bilateral renal tumors
have been reported [46, 48].
Other associated tumors
Infrequently, a broad range of other benign and malignant tumors
has also been observed in MCUL/HLRCC families, including breast
carcinoma, prostate carcinoma, bladder carcinoma, testis Leydig
cell tumors, cerebral cavernomas, ovarian and kidney cysts, and
adrenal gland adenomas [48-53]. Some of these tumors showed
biallelic FH inactivation, indicating that they are associated with
MUCL/HLRCC. However, the majority of tumors observed in these
families most probably occurred by coincidence and, thus, it seems
rather unlikely that they are pathogenetically associated with
hereditary cutaneous leiomyomatosis.
Histopathological findings
Cutaneous leiomyomas and leiomyosarcoma
Piloleiomyomas are poorly circumscribed lesions consisting of
interlacing bundles of smooth muscle fibers intermingled with
varying amounts of collagen bundles (figure 2A). The neoplasms
are located in the dermis and may encroach upon the subcutaneous
tissue. The smooth muscle fibers usually show an eosinophilic
cytoplasm with typical cigar shaped nuclei (figure 2B).
Immunohistochemistry reveals positive staining with anti-desmin and
anti-α-smooth muscle actin [10] (figure 2C).
Similarly to cutaneous leiomyomas, cutaneous leiomyosarcoma show
a poorly demarcated dermal tumor composed of proliferative bundles
of spindle cells intermingled with collagen fibers with positive
immunohistochemical staining for anti-α-smooth muscle actin and
desmin. Additionally, however, mitotic figures and atypical cells
are present [10].
Uterine leiomyomas and leiomyosarcoma
Uterine leiomyosarcoma are characterized by whirled bundles of
elongated smooth-muscle cells that are closely packed so that the
tumor appears to be more cellular. The nuclei of cells are
elongated and uniform. Mitosis figures are absent or sparse [54].
In contrast, uterine leiomyosarcoma show mitotic activity, nuclear
atypia, and tumor necrosis [55].
Renal cancer
Type II papillary RCC is characterized by a papillary growth
pattern with thick, lengthened papillae. The cells lining the
papillae are large with abundant cytoplasm and display a high
Fuhrman nuclear grade (3 or 4) with large and prominent
“owl-eye-like” nuclei [8, 46, 56, 57]. Furthermore,
tubulo-papillary, tubular, and cystic growth patterns can be found
in HLRCC related kidney malignancies. Recently, Merino et al.
reviewed 40 RCCs from HLRCC patients. According to their
observations, the hallmark of these tumors is the presence of large
eosinophilic nucleoli with a clear perinuclear halo, regardless of
the prevailing histological pattern. Moreover, they state that this
feature is not only seen in the majority of the tumor cells but is
unique to HLRCC kidney tumors [46]. Although a specific
immunophenotype has not yet been established for HLRCC-associated
renal tumors, absent expression of cytokeratin 7 (CK7) and Ulex
europeaus agglutinin (UEA-1) may support the diagnosis [46].
Utilization of FH antibodies could also contribute to the diagnosis
of an HLRCC-related malignant tumor.
Diagnosis
All patients with a tentative diagnosis of cutaneous leiomyomatosis
should be examined by a dermatologist. To exclude the differential
diagnoses of eruptive syringoma, neurofibroma, neurinoma or eccrine
spiradenoma, a biopsy for histopathological examination must be
obtained to confirm the diagnosis because the histological features
of cutaneous leiomyomas are highly specific and will help to
differentiate it from other tumors with similar clinical
appearances. In a patient with histologically confirmed cutaneous
leiomyomas, taking a detailed family history is mandatory to
identify putative relatives at risk and arrange for genetic
counseling and additional screening for uterine leiomyomas and
kidney cancer. DNA mutation analysis of the FH gene is compulsory
in order to confirm the diagnosis on the molecular genetic level
and should nowadays be considered as a state-of-the-art diagnostic
technique.
Gene and function
In 2001, Alam and colleagues reported linkage of MCUL to chromosome
1q42.3-q43 [32, 58]. Subsequently, heterozygous germline mutations
in the fumarate hydratase (FH) gene were detected in both MCUL and
HLRCC, confirming that these disorders are allelic [9, 41]. The FH
gene spans 22 kb and contains 10 exons. To date, approximately 73
different mutations distributed throughout the FH gene have been
reported in cutaneous leiomyomatosis [9, 19, 20, 26, 31, 41, 42,
45, 48-53, 59-73]. These sequence deviations include missense,
nonsense, frameshift, and splice-site mutations as well as whole
gene and exonic deletions and, together, demonstrate the molecular
heterogeneity associated with disorders caused by FH mutations
(figure 3).
Currently, there is no strong evidence for a putative
genotype-phenotype correlation in cutaneous leiomyomatosis.
Previous reports suggested that FH mutations occurring at 5’ of
codon 250 of FH could be associated with an increased risk of
developing renal cell cancer [9]. However, a subsequent study from
Toro et al. showed that only 55% of FH mutations in HLRCC were
indeed located at 5’ of codon 250, a notion that was confirmed by
Wei et al. who reported on FH mutations distributed over the
entire gene in HLRCC families. Of these mutations, only a few were
located upstream of codon 250 of FH [41, 42]. In addition, there
are no reports on families in which more than one individual
developed kidney cancer. Therefore, a heterozygous germline
mutation alone is most likely not sufficient to give rise to renal
cancer, suggesting an important role of additional genetic
inactivation by, e.g. LOH or a second hit mutation in the
development of kidney cancer.
Homozygous or compound heterozygous FH germline mutations cause
autosomal recessive fumarate hydratase deficiency (FHD) (OMIM
136850), a severe metabolic disease characterized by neurological
impairment and encephalopathy [74]. To date, neither the occurrence
of leiomyomas nor renal cancer has been reported in individuals
affected with FHD. This may be due to the fact that most
individuals suffering from FHD only live a few months and do not
reach early adulthood [74]. FH codes for the enzyme fumarate
hydratase (FH) that catalyzes the conversion of fumarate to malate
in the Krebs cycle [9]. FH is thought to act as tumor suppressor
since loss of the wild-type allele has been found in cutaneous,
uterine, and renal tumors of patients with MCUL and HLRCC [9, 41].
Furthermore, enzymatic FH activity was low or absent in tumors from
affected individuals [75].
The exact mechanism by which improper FH function leads to tumor
formation has not yet been defined. However, recent studies suggest
a pseudohypoxic drive in the pathogenesis of tumors in HLRCC [76,
77]. Considering the position of the enzyme in the Krebs cycle,
loss of mitochondrial FH leads to an intracellular accumulation of
fumarate. Elevated intracellular levels of fumarate have been shown
to stabilize the transcription factors hypoxia-inducible factor
(HIF-1α and HIF-2α) [77]. HIF proteins are key regulators of oxygen
homeostasis and act via transcriptional regulation of
anti-apoptotic and proliferative genes, such as vascular
endothelial growth factor (VEGF), platelet derived growth factor
(PDGF), endothelial growth factor receptor (EGFR), glucose
transporter protein 1 (Glut-1), and transforming growth factor-α
(TGF-α). Overexpression of these gene products is associated with
improved vascularity, autocrine stimulation, uncontrolled growth,
and survival of the cell [76, 78, 79]. This phenomenon has been
described as the “pseudohypoxia” and shows remarkable similarities
with von Hippel Lindau (VHL) syndrome [80-82]. Increased expression
of HIF-1α, HIF-2α and Glut-1 was recently detected in kidney tumors
from patients with HLRCC [77]. Additional studies on leiomyomas
occurring in the context of HLRCC revealed an enhanced expression
of VEGF, further supporting the role of a pseudohypoxic drive as
the link between mitochondrial FH dysfunction and tumor formation
in HLRCC [76].
Multidisciplinary management
Genetic counseling of patients and their relatives should be
self-evident. Once the diagnosis of hereditary cutaneous
leiomyomatosis is made, affected individuals must be considered at
risk for the occurrence of other tumors. Women with MCUL/HLRCC have
a high chance of developing uterus leiomyomas at young age, often
necessitating hysterectomy. Further, they have a slightly increased
risk for the occurrence of highly aggressive uterine
leiomyosarcoma. Therefore, referral of all female patients with FH
mutations to a gynecologist for annual evaluation seems justified
in our eyes. Additionally, adequate counseling for family planning
is advisable, considering that in these patients uterine leiomyomas
usually develop early.
The precise risk for the development of renal cancer in HLRCC is
not known. The overall frequency of malignant kidney tumors in
familial cutaneous leiomyoma is variable, ranging from 1-14% when
looking at different studies [41, 60, 62]. Likewise, age of onset
varies from 16 to 90 years [41, 46, 60, 62]. Renal malignancies in
HLRCC are associated with a poor prognosis and frequently
metastasize to regional lymph nodes. Of note though, there are no
specific screening guidelines for HLRCC, most likely due to the
rareness of the disease. We suggest that annual abdominal
computational tomography could serve as a screening procedure for
both the detection of kidney tumors and uterine changes. Magnetic
resonance imaging and ultrasound could serve as alternative
techniques if contrast-enhanced computational tomography cannot be
performed. However, ultrasound alone cannot be considered an
adequate screening technique since lesions may be isoechoic and
therefore, may be missed. Magnetic resonance imaging of the uterus
is particularly helpful in detecting and characterizing uterine
leiomyomas and leiomyosarcoma [83].
Therapy
Cutaneous leiomyoma and leiomyosarcoma
On the one hand, cutaneous leiomyomas may cause cosmetic
discomfort. Moreover, recurrent pain arising in these tumors can
cause serious complaints and disturb daily activities, sometimes
even leading to suicidal thoughts. While solitary leiomyomas can be
easily treated by surgical excision, multiple leiomyomas covering
large surfaces of the body are difficult to manage. Several
different treatment modalities have been hitherto described for
symptomatic pain relief or tumor destruction in cutaneous
leiomyomatosis, including pharmacological agents such as
nifedipine, gabapentine, doxasozine, phenoxybenzamine, hyoscine,
hydrobromide, and nitroglycerine or invasive therapy consisting of
extensive surgical excision, CO2 laser ablation and
cryotherapy, all with variable success [2, 7, 11, 12, 14, 37,
84-93]. Unfortunately, some patients with severe complaints do not
respond to any of these treatment modalities. Hence, there is a
need for additional therapeutic strategies, particularly for
patients suffering from extensive painful leiomyomas.
Most of the current therapeutic recommendations for cutaneous
leiomyosarcoma include a wide surgical excision. Routine lymph node
excision is not indicated unless lymph node invasion is evident.
Radiotherapy could be an option if surgery is unfeasible. However,
recurrence rates are very high [10, 94].
Uterine leiomyoma and leiomyosarcoma
Different surgical approaches, including myomectomy, hysterectomy
or abdominal uterus extirpation can be considered. Prior to
recommending a specific therapy the patient’s individual concerns
should always be respected though, in particular the specific
symptoms and their effect on quality of life and the possible
request to preserve fertility [95, 96].
As a general rule, hysterectomy is the first treatment of choice
for patients with uterine malignancies. Peritoneal washing and
omentectomy are indicated if the diagnosis of leiomyosarcoma is
sure. The role of prophylactic lymphadenectomy is limited since a
high percentage of patients without lymph node metastases will
still experience a recurrence. Myomectomy may be considered in
patients with low stage leiomyosarcoma who strongly desire future
fertility [97].
Renal cancer
Only little is known about the treatment of kidney malignancies in
HLRCC but since these tumors behave aggressively, total nephrectomy
at early stage is indicated. Recent advances in the understanding
of the molecular pathways involved in the etiopathogenesis of RCC
have led to the early development of promising targeted therapies
in hereditary malignant kidney tumors [98, 99].
Acknowledgements
JF is a board member of the Dutch working group on hereditary
leiomyomatosis and a member of the Network for Ichthyoses and
Related Keratinization Disorders (NIRK) that is supported by the
German Federal Ministry of Education and Research (BMBF). We thank
Dr. A. van Marion, MD, for providing the histological pictures.
Financial support: none. Conflict of interest: none.
References
1 Virchow R. Über Makroglossie und pathologische Neubildung
quergestreifter Muskelfasern. Virchows Arch Pathol Anat 1854; 7:
126-38.
2 Fischer Z, Helwig E. Leiomyomas of the skin. Arch
Dermatol 1963; 88: 510-20.
3 Kloepfer HW, Krafchuk J, Derbes V,
Burks J. Hereditary multiple leiomyoma of the skin. Am J Hum
Genet 1958; 10: 48-52.
4 Guillet G, Grau P, Sassolas B, Zagnoli A,
Leroy JP, Labouche F. Leiomyomes cutanes multiples et
fibromes uterins: a propos d’une observation d’un cas non familial.
Semin Hop Paris 1987; 63: 65-7.
5 Mezzadra G. Multiple hereditary cutaneous leiomyoma.
Study of a systemic case in a male subject related to a family with
cutaneous leiomyomatosis and uterine fibromyomatosis. Minerva
Dermatol 1965; 40: 388-93.
6 Rudner EJ, Schwartz OD, Greekin JN. Multiple
cutaneous leiomyoma in identical twins. Arch Derm 1972; 104:
81-2.
7 Reed WB, Walker R, Horowitz R. Cutaneous
leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973; 53:
409-16.
8 Launonen V, Vierimaa O, Kiuru M, et al.
Inherited susceptibility to uterine leiomyomas and renal cell
cancer. Proc Natl Acad Sci U S A 2001; 98: 3387-92.
9 Tomlinson IP, Alam NA, Rowan AJ, et al.
Germline mutations in FH predispose to dominantly inherited uterine
fibroids, skin leiomyomata and papillary renal cell cancer. Nat
Genet 2002; 30: 406-10.
10 Holst VA, Junkins-Hopkins JM, Elenitsas R.
Cutaneous smooth muscle neoplasms: clinical features, histologic
findings, and treatment options. J Am Acad Dermatol 2002; 46:
477-90.
11 Archer CB, Greaves MW. Assessment of treatment for
painful cutaneous leiomyomas. J Am Acad Dermatol 1987; 17:
141-2.
12 Archer CB, Whittaker S, Greaves MW.
Pharmacological modulation of cold-induced pain in cutaneous
leiomyomata. Br J Dermatol 1988; 118: 255-60.
13 Montgomery H, Winkelmann RK. Smooth-muscle tumors of the
skin. AMA Arch Derm 1959; 79: 32-40; discussion 40-31.
14 Thyresson HN, Su WP. Familial cutaneous
leiomyomatosis. J Am Acad Dermatol 1981; 4: 430-4.
15 Mann PR. Leiomyoma cutis: an electron microscope study.
Br J Dermatol 1970; 82: 463-9.
16 Raj S, Calonje E, Kraus M, Kavanagh G,
Newman PL, Fletcher CD. Cutaneous pilar leiomyoma:
clinicopathologic analysis of 53 lesions in 45 patients. Am J
Dermatopathol 1997; 19: 2-9.
17 Agarwalla A, Thakur A, Jacob M, Joshi A,
Garg VK, Agrawal S. Zosteriform and disseminated lesions
in cutaneous leiomyoma. Acta Derm Venereol 2000; 80: 446.
18 Fleta Asín B, Berzal Rosende M, Carrillo
Gijón R, Fernández-Guarino M, Jaén Olásolo P. Type 2
segmental cutaneous leiomyomatosis: an example of mosaicism. Eur J
Dermatol 2009; 19: 183-4.
19 Badeloe S, Bladergroen RS, Jonkman MF,
et al. Hereditary multiple cutaneous leiomyoma resulting from
novel mutations in the fumarate hydratase gene. J Dermatol Sci
2008; 51: 139-43.
20 Badeloe S, van Geel M, van Steensel MA,
et al. Diffuse and segmental variants of cutaneous
leiomyomatosis: novel mutations in the fumarate hydratase gene and
review of the literature. Exp Dermatol 2006; 15: 735-41.
21 Badeloe S, van Geel M, van Steensel MA,
Steijlen PM, Poblete-Gutierrez P, Frank JA. From
gene to disease; cutaneous leiomyomatosis. Ned Tijdschr Geneeskd
2007; 151: 300-4.
22 Berendes U, Kuhner A, Schnyder UW. Segmentary
and disseminated lesions in multiple hereditary cutaneous
leiomyoma. Humangenetik 1971; 13: 81-2.
23 Happle R. Segmental forms of autosomal dominant skin
disorders: different types of severity reflect different states of
zygosity. Am J Med Genet 1996; 66: 241-2.
24 Happle R. Segmental type 2 manifestation of autosome
dominant skin diseases. Development of a new formal genetic
concept. Hautarzt 2001; 52: 283-7.
25 Happle R. Dohi Memorial Lecture. New aspects of
cutaneous mosaicism. J Dermatol 2002; 29: 681-92.
26 Huter E, Wortham NC, Hartschuh W, Enk A,
Jappe U. Single base mutation in the fumarate hydratase gene
leading to segmental cutaneous leiomyomatosis. Acta Derm Venereol
2008; 88: 63-5.
27 Konig A. Segmental leiomyomatosis: from haplotype to
type Happle. J Dtsch Dermatol Ges 2005; 3: 671-2.
28 Konig A, Happle R. Two cases of type 2 segmental
manifestation in a family with cutaneous leiomyomatosis. Eur J
Dermatol 2000; 10: 590-2.
29 Konig A, Happle R. Type 2 segmental cutaneous
leiomyomatosis. Acta Derm Venereol 2001; 81: 383.
30 Lang K, Reifenberger J, Ruzicka T,
Megahed M. Type 1 segmental cutaneous leiomyomatosis. Clin Exp
Dermatol 2002; 27: 649-50.
31 Martinez-Mir A, Glaser B, Chuang GS,
et al. Germline fumarate hydratase mutations in families with
multiple cutaneous and uterine leiomyomata. J Invest Dermatol 2003;
121: 741-4.
32 Martinez-Mir A, Gordon D, Horev L, et al.
Multiple cutaneous and uterine leiomyomas: refinement of the
genetic locus for multiple cutaneous and uterine leiomyomas on
chromosome 1q42.3-43. J Invest Dermatol 2002; 118: 876-80.
33 Renner R, Sticherling M. Familial occurrence of a
type 2 segmental manifestation of cutaneous leiomyomatosis. J Dtsch
Dermatol Ges 2005; 3: 695-9.
34 Richter G. Primary segmental localization of multiple
leiomyomas. Hautarzt 1965; 16: 177-9.
35 Ritzmann S, Hanneken S, Neumann NJ,
Ruzicka T, Kruse R. Type 2 segmental manifestation of
cutaneous leiomyomatosis in four unrelated women with additional
uterine leiomyomas (Reed’s Syndrome). Dermatology 2006; 212:
84-7.
36 Sada A, Misago N, Inoue T, Narisawa Y.
Segmental multiple cutaneous piloleiomyoma with an overlying
epidermal proliferation. J Dermatol 2007; 34: 665-7.
37 Smith CG, Glaser DA, Leonardi C. Zosteriform
multiple leiomyomas. J Am Acad Dermatol 1998; 38: 272-3.
38 Suwattee P, Dakin C. Bilateral segmental
leiomyomas: a case report and review of the literature. Cutis 2008;
82: 33-6.
39 Tsoitis G, Kanitakis J, Papadimitriou C,
Hatzibougias Y, Asvesti K, Happle R. Cutaneous
leiomyomatosis with type 2 segmental involvement. J Dermatol 2001;
28: 251-5.
40 Poblete-Gutierrez P, Wiederholt T, Konig A,
et al. Allelic loss underlies type 2 segmental Hailey-Hailey
disease, providing molecular confirmation of a novel genetic
concept. J Clin Invest 2004; 114: 1467-74.
41 Toro JR, Nickerson ML, Wei MH, et al.
Mutations in the fumarate hydratase gene cause hereditary
leiomyomatosis and renal cell cancer in families in North America.
Am J Hum Genet 2003; 73: 95-106.
42 Wei MH, Toure O, Glenn GM, et al. Novel
mutations in FH and expansion of the spectrum of phenotypes
expressed in families with hereditary leiomyomatosis and renal cell
cancer. J Med Genet 2006; 43: 18-27.
43 Stewart EA. Uterine fibroids. Lancet 2001; 357:
293-8.
44 Kim G. Multiple cutaneous and uterine leiomyomatosis
(Reed’s syndrome). Dermatol Online J 2005; 11: 21.
45 Ylisaukko-oja SK, Kiuru M, Lehtonen HJ,
et al. Analysis of fumarate hydratase mutations in a
population-based series of early onset uterine leiomyosarcoma
patients. Int J Cancer 2006; 119: 283-7.
46 Merino MJ, Torres-Cabala C, Pinto P,
Linehan WM. The morphologic spectrum of kidney tumors in
hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
syndrome. Am J Surg Pathol 2007; 31: 1578-85.
47 Badeloe S, van Spaendonck-Zwarts KY, van
Steensel MA, et al. Wilms tumour as a possible early
manifestation of hereditary leiomyomatosis and renal cell cancer?
Br J Dermatol 2009; 160: 707-9.
48 Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK,
et al. Increased risk of cancer in patients with fumarate
hydratase germline mutation. J Med Genet 2006; 43: 523-6.
49 Kiuru M, Launonen V. Hereditary leiomyomatosis and
renal cell cancer (HLRCC). Curr Mol Med 2004; 4: 869-75.
50 Lehtonen HJ, Blanco I, Piulats JM,
Herva R, Launonen V, Aaltonen LA. Conventional renal
cancer in a patient with fumarate hydratase mutation. Human
pathology 2007; 38: 793-6.
51 Varol A, Stapleton K, Roscioli T. The syndrome
of hereditary leiomyomatosis and renal cell cancer (HLRCC): The
clinical features of an individual with a fumarate hydratase gene
mutation. Australas J Dermatol 2006; 47: 274-6.
52 Campione E, Terrinoni A, Orlandi A,
et al. Cerebral cavernomas in a family with multiple cutaneous
and uterine leiomyomas associated with a new mutation in the
fumarate hydratase gene. J Invest Dermatol 2007; 127: 2271-3.
53 Carvajal-Carmona LG, Alam NA, Pollard PJ,
et al. Adult leydig cell tumors of the testis caused by
germline fumarate hydratase mutations. J Clin Endocrinol Metab
2006; 91: 3071-5.
54 Robboy SJ, Bentley RC, Butnor K,
Anderson MC. Pathology and pathophysiology of uterine
smooth-muscle tumors. Environ Health Perspect 2000; 108 (Suppl 5):
779-84.
55 Toledo G, Oliva E. Smooth muscle tumors of the
uterus: a practical approach. Arch Pathol Lab Med 2008; 132:
595-605.
56 Delahunt B, Eble JN. Papillary renal cell
carcinoma: a clinicopathologic and immunohistochemical study of 105
tumors. Mod Pathol 1997; 10: 537-44.
57 Delahunt B, Eble JN, McCredie MR,
Bethwaite PB, Stewart JH, Bilous AM. Morphologic
typing of papillary renal cell carcinoma: comparison of growth
kinetics and patient survival in 66 cases. Human pathology 2001;
32: 590-5.
58 Alam NA, Bevan S, Churchman M, et al.
Localization of a gene (MCUL1) for multiple cutaneous leiomyomata
and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001;
68: 1264-9.
59 Alam NA, Barclay E, Rowan AJ, et al.
Clinical features of multiple cutaneous and uterine leiomyomatosis:
an underdiagnosed tumor syndrome. Arch Dermatol 2005; 141:
199-206.
60 Alam NA, Olpin S, Leigh IM. Fumarate hydratase
mutations and predisposition to cutaneous leiomyomas, uterine
leiomyomas and renal cancer. Br J Dermatol 2005; 153: 11-7.
61 Alam NA, Olpin S, Rowan A, et al.
Missense mutations in fumarate hydratase in multiple cutaneous and
uterine leiomyomatosis and renal cell cancer. J Mol Diagn 2005; 7:
437-43.
62 Alam NA, Rowan AJ, Wortham NC, et al.
Genetic and functional analyses of FH mutations in multiple
cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and
renal cancer, and fumarate hydratase deficiency. Human molecular
genetics 2003; 12: 1241-52.
63 Bayley JP, Launonen V, Tomlinson IP. The FH
mutation database: an online database of fumarate hydratase
mutations involved in the MCUL (HLRCC) tumor syndrome and
congenital fumarase deficiency. BMC Med Genet 2008; 9: 20.
64 Chan I, Wong T, Martinez-Mir A,
Christiano AM, McGrath JA. Familial multiple cutaneous
and uterine leiomyomas associated with papillary renal cell cancer.
Clin Exp Dermatol 2005; 30: 75-8.
65 Chuang GS, Martinez-Mir A, Engler DE,
Gmyrek RF, Zlotogorski A, Christiano AM. Multiple
cutaneous and uterine leiomyomata resulting from missense mutations
in the fumarate hydratase gene. Clin Exp Dermatol 2006; 31:
118-21.
66 Dereure O. Mutations in fumarate hydratase during
cutaneous and uterine leiomyomatosis associated with renal cancer.
Ann Dermatol Venereol 2005; 132: 300.
67 Heinritz W, Paasch U, Sticherling M,
et al. Evidence for a founder effect of the germline fumarate
hydratase gene mutation R58P causing hereditary leiomyomatosis and
renal cell cancer (HLRCC). Ann Hum Genet 2008; 72: 35-40.
68 Kiuru M, Lehtonen R, Arola J, et al. Few
FH mutations in sporadic counterparts of tumor types observed in
hereditary leiomyomatosis and renal cell cancer families. Cancer
Res 2002; 62: 4554-7.
69 Lehtonen R, Kiuru M, Vanharanta S, et al.
Biallelic inactivation of fumarate hydratase (FH) occurs in
nonsyndromic uterine leiomyomas but is rare in other tumors. Am J
Pathol 2004; 164: 17-22.
70 Makino T, Nagasaki A, Furuichi M, et al.
Novel mutation in a fumalate hydratase gene of a Japanese patient
with multiple cutaneous and uterine leiomyomatosis. J Dermatol Sci
2007; 48: 151-3.
71 Chuang GS, Martinez-Mir A, Geyer A,
et al. Germline fumarate hydratase mutations and evidence for
a founder mutation underlying multiple cutaneous and uterine
leiomyomata. J Am Acad Dermatol 2005; 52: 410-6.
72 Ahvenainen T, Lehtonen HJ, Lehtonen R,
et al. Mutation screening of fumarate hydratase by multiplex
ligation-dependent probe amplification: detection of exonic
deletion in a patient with leiomyomatosis and renal cell cancer.
Cancer Genet Cytogenet 2008; 183: 83-8.
73 Ylisaukko-oja SK, Cybulski C, Lehtonen R,
et al. Germline fumarate hydratase mutations in patients with
ovarian mucinous cystadenoma. Eur J Hum Genet 2006; 14: 880-3.
74 Gellera C, Uziel G, Rimoldi M, et al.
Fumarase deficiency is an autosomal recessive encephalopathy
affecting both the mitochondrial and the cytosolic enzymes.
Neurology 1990; 40: 495-9.
75 Pithukpakorn M, Wei MH, Toure O, et al.
Fumarate hydratase enzyme activity in lymphoblastoid cells and
fibroblasts of individuals in families with hereditary
leiomyomatosis and renal cell cancer. J Med Genet 2006; 43:
755-62.
76 Bratslavsky G, Sudarshan S, Neckers L,
Linehan WM. Pseudohypoxic pathways in renal cell carcinoma.
Clin Cancer Res 2007; 13: 4667-71.
77 Isaacs JS, Jung YJ, Mole DR, et al. HIF
overexpression correlates with biallelic loss of fumarate hydratase
in renal cancer: novel role of fumarate in regulation of HIF
stability. Cancer Cell 2005; 8: 143-53.
78 Linehan WM, Vasselli J, Srinivasan R,
et al. Genetic basis of cancer of the kidney: disease-specific
approaches to therapy. Clin Cancer Res 2004; 10: 6282S-6289S.
79 Linehan WM, Walther MM, Zbar B. The genetic
basis of cancer of the kidney. J Urol 2003; 170: 2163-72.
80 Ivan M, Kondo K, Yang H, et al. HIFalpha
targeted for VHL-mediated destruction by proline hydroxylation:
implications for O2 sensing. Science 2001; 292: 464-8.
81 Kondo K, Kaelin Jr WG. The von Hippel-Lindau
tumor suppressor gene. Exp Cell Res 2001; 264: 117-25.
82 Kondo K, Klco J, Nakamura E,
Lechpammer M, Kaelin Jr WG. Inhibition of HIF is
necessary for tumor suppression by the von Hippel-Lindau protein.
Cancer Cell 2002; 1: 237-46.
83 Choyke PL. Imaging of hereditary renal cancer. Radiol
Clin North Am 2003; 41: 1037-51.
84 Abraham Z, Cohen A, Haim S. Muscle relaxing
agent in cutaneous leiomyoma. Dermatologica 1983; 166: 255-6.
85 Alam M, Rabinowitz AD, Engler DE. Gabapentin treatment of
multiple piloleiomyoma-related pain. J Am Acad Dermatol 2002; 46(2
Suppl Case Reports): S27-9.
86 Batchelor RJ, Lyon CC, Highet AS. Successful
treatment of pain in two patients with cutaneous leiomyomata with
the oral alpha-1 adrenoceptor antagonist, doxazosin. Br J Dermatol
2004; 150: 775-6.
87 Christenson LJ, Smith K, Arpey CJ. Treatment
of multiple cutaneous leiomyomas with CO2 laser ablation. Dermatol
Surg 2000; 26: 319-22.
88 Engelke H, Christophers E. Leiomyomatosis cutis et
uteri. Acta Derm Venereol Suppl (Stockh) 1979; 59: 51-4.
89 George S, Pulimood S, Jacob M, Chandi SM.
Pain in multiple leiomyomas alleviated by nifedipine. Pain 1997;
73: 101-2.
90 Thompson Jr JA. Therapy for painful cutaneous
leiomyomas. J Am Acad Dermatol 1985; 13: 865-7.
91 Tiffee JC, Budnick SD. Multiple cutaneous
leiomyomas. Report of a case. Oral Surg Oral Med Oral Pathol 1993;
76: 716-7.
92 Venencie PY, Puissant A, Boffa GA,
Sohier J, Duperrat B. Multiple cutaneous leiomyomata and
erythrocytosis with demonstration of erythropoietic activity in the
cutaneous leiomyomata. Br J Dermatol 1982; 107: 483-6.
93 Yaghoobi R, Mossavi Z. Mohammad poor M. Multiple
papular and nodular lesions on the extremities and trunk. Arch
Dermatol 1999; 135: 343-6.
94 Porter CJ, Januszkiewicz JS. Cutaneous
leiomyosarcoma. Plast Reconstr Surg 2002; 109: 964-7.
95 Wallach EE, Vlahos NF. Uterine myomas: an overview
of development, clinical features, and management. Obstet Gynecol
2004; 104: 393-406.
96 Wallach EE, Vu KK. Myomata uteri and infertility.
Obstet Gynecol Clin North Am 1995; 22: 791-9.
97 Reed NS. The management of uterine sarcomas. Clin Oncol
(R Coll Radiol) 2008; 20: 470-8.
98 Brugarolas J. Renal-cell carcinoma--molecular pathways
and therapies. N Engl J Med 2007; 356: 185-7.
99 Refae MA, Wong N, Patenaude F, Begin LR,
Foulkes WD. Hereditary leiomyomatosis and renal cell cancer:
an unusual and aggressive form of hereditary renal carcinoma. Nat
Clin Pract Oncol 2007; 4: 256-61.
|
Printable version
Version PDF
